Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD

Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneuromyelitisoptica spectrum disorder (NMOSD) will be presentedBasel, 02 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new data for OCREVUS ® (ocrelizumab) and investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib for multiple sclerosis (MS), and ENSPRYNG® (satralizumab) for neuromyelitis optica spectrum disorder (NMOSD). In total, Roche will be presenting 36 abstracts at the 9th Joint ECTRIMS-ACTRIMS Meeting (Europe an and Americas Committees for Treatment and Research in Multiple Sclerosis) from 11-13 October 2023. Late-breaking data in MS includes the Phase Ib OCARINA I and Phase III OCARINA II studies evaluating an investigational subcutaneous OCREVUS injection. In addition, the Phase II FENopta study of fen ebrutinib for people living with MS and late-breaking ENSPRYNG data for people with NMOSD, which includes longer-term...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news